Geron Corp - GERN STOCK NEWS

Geron Corporation (Nasdaq: GERN) has initiated dosing for the first patient in its Phase 3 clinical trial, IMpactMF, studying imetelstat for refractory myelofibrosis (MF), with overall survival as the primary endpoint. This trial, targeting 320 patients, addresses a significant unmet need given the median overall survival of 14-16 months for those unresponsive to JAK inhibitors. Interim results are anticipated in 2024, with final results expected in 2025. Imetelstat is also Fast Track designated by the FDA for certain patient populations, enhancing its development prospects.

Geron Corporation (Nasdaq: GERN) announced the issuance of non-statutory stock options for 240,000 shares to newly hired employees. These options were granted on March 17, 2021, at an exercise price of $1.81 per share, matching the stock's closing price on that date. The options have a 10-year term and vest over four years, with 12.5% vesting after six months of employment. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of Geron's 2018 Inducement Award Plan aimed at attracting new talent.

Geron Corporation (Nasdaq: GERN) reported its financial results for Q4 and FY 2020, ending with $260 million in cash and marketable securities, expected to last until late 2022. The company is advancing its Phase 3 trials for imetelstat in hematologic malignancies, with IMerge Phase 3 expected to be fully enrolled in H2 2021. However, COVID-19 has caused delays in enrollment. Fiscal 2020 net loss was $75.6 million, with revenues of $253,000. Geron anticipates operating expenses between $108 and $112 million in 2021 while preparing for a potential NDA submission in 2023.

Geron Corporation (Nasdaq: GERN) will announce its fourth quarter and full year 2020 financial results on March 11, 2021, after market close. A conference call will follow at 4:30 p.m. ET to discuss these results and recent developments. Interested participants can access the call via a pre-registration link. Geron focuses on developing imetelstat, a telomerase inhibitor, currently being tested in two Phase 3 trials: IMerge for lower-risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis. More details are available on their website.

Geron Corporation (Nasdaq: GERN) has granted non-statutory stock options totaling 431,600 shares to newly hired employees as part of their employment incentives. The options, issued on February 17, 2021, have an exercise price of $1.99 per share, aligning with Geron's closing stock price on the grant date. The vesting period is set over four years, beginning with 12.5% at six months, followed by equal installments thereafter. This grant adheres to Nasdaq rules and is part of Geron's 2018 Inducement Award Plan.

Geron focuses on developing imetelstat, a telomerase inhibitor, in hematologic malignancies.

Geron Corporation (Nasdaq: GERN) announced the grant of non-statutory stock options for 120,000 shares of common stock to newly hired employees as an employment inducement. The options were granted on January 20, 2021, with an exercise price of $1.74 per share, matching the closing stock price on the grant date. These options have a 10-year term and vest over four years. This action complies with Nasdaq Listing Rule 5635(c)(4) and aligns with Geron's 2018 Inducement Award Plan. Geron is focused on developing imetelstat, a telomerase inhibitor, in hematologic cancers.

Geron Corporation (Nasdaq: GERN) announced that CEO John A. Scarlett will present a company overview at the B. Riley Securities Virtual Oncology Investor Conference on January 20 at 3:00 p.m. ET. The presentation will be accessible via a live audio webcast on Geron's website, with a replay available for 30 days post-event.

Geron focuses on developing imetelstat, a first-in-class telomerase inhibitor targeting hematologic myeloid malignancies. For further details, visit www.geron.com.

Geron Corporation (Nasdaq: GERN) has announced the launch of the IMpactMF Phase 3 clinical trial for imetelstat, a telomerase inhibitor targeting refractory myelofibrosis (MF). This trial aims to enroll approximately 320 patients and assess the drug's ability to extend overall survival and improve symptoms, following promising Phase 2 results. The primary endpoint will focus on overall survival, with secondary endpoints covering various clinical outcomes. The trial incorporates over 150 sites globally, though potential COVID-19-related delays are acknowledged.

Geron Corporation (Nasdaq: GERN) has achieved fifty percent enrollment in the IMerge Phase 3 clinical trial for imetelstat, targeting lower risk myelodysplastic syndromes (MDS). This milestone is crucial for advancing the trial, which aims to assess transfusion independence and disease-modifying effects of imetelstat. The trial is set to enroll approximately 170 patients, with top-line results expected in the second half of 2022, provided enrollment completes by mid-2021.

Imetelstat is the first telomerase inhibitor in development, offering a potential treatment alternative for MDS patients.